Advertisement

Continuous Glucose Monitoring and Antidiabetic Therapies

  • J. Zhou
  • W. Jia
Chapter

Abstract

Glycemic variability is one of the important aspects of blood glucose management in diabetes. Several studies have shown that glycemic variability is closely related to chronic complications of diabetes. Therefore, reducing glycemic variability is an important component in the antidiabetic therapies. This chapter focuses on clinical trials that used continuous glucose monitoring (CGM) to assess the efficacy of three aspects of the antidiabetic therapy: insulin therapy, oral hypoglycemic agents, and combination therapy with oral hypoglycemic agents and insulin. With a deep understanding of glycemic variability, CGM will be an effective tool in assessing the efficacy of antidiabetic therapies, providing a detailed basis for developing more effective antidiabetic therapies.

Keywords

Continuous glucose monitoring Glycemic variability Antidiabetic therapy 

References

  1. 1.
    Zhou J, Jia W, Bao Y, Ma X, Lu W, Li H, Hu C, Xiang K. Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med Sci Monit. 2008;14:CR552–8.PubMedGoogle Scholar
  2. 2.
    Alemzadeh R, Palma-Sisto P, Holzum M, Parton E, Kicher J. Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus. Diabetes Technol Ther. 2007;9:339–47.  https://doi.org/10.1089/dia.2006.0038.CrossRefPubMedGoogle Scholar
  3. 3.
    McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30:1044–8.  https://doi.org/10.2337/dc06-1328.CrossRefPubMedGoogle Scholar
  4. 4.
    Jendle J, Testa MA, Martin S, Jiang H, Milicevic Z. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. Diabetes Obes Metab. 2016;18:999–1005.  https://doi.org/10.1111/dom.12705.CrossRefPubMedGoogle Scholar
  5. 5.
    Tosaka Y, Kanazawa A, Ikeda F, Iida M, Sato J, Matsumoto K, Uchida T, Tamura Y, Ogihara T, Mita T, Shimizu T, Goto H, Ohmura C, Fujitani Y, Watada H. Switching from twice-daily basal insulin injections to once-daily insulin degludec injection for basal-bolus insulin regimen in japanese patients with type 1 diabetes: a pilot study. Int J Endocrinol. 2015;2015:176261.  https://doi.org/10.1155/2015/176261.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ma Z, Chen R, Liu Y, Yu P, Chen L. Effect of liraglutide vs. NPH in combination with metformin on blood glucose fluctuations assessed using continuous glucose monitoring in patients with newly diagnosed type 2 diabetes. Int J Clin Pharmacol Ther. 2015;53:933–9.  https://doi.org/10.5414/CP202415.CrossRefPubMedGoogle Scholar
  7. 7.
    Bao YQ, Zhou J, Zhou M, Cheng YJ, Lu W, Pan XP, Tang JL, Lu HJ, Jia WP. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed type 2 diabetes. Clin Exp Pharmacol Physiol. 2010;37:564–8.  https://doi.org/10.1111/j.1440-1681.2010.05361.x.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhou J, Li H, Zhang X, Peng Y, Mo Y, Bao Y, Jia W. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes. Diabetes Technol Ther. 2013;15:481–8.  https://doi.org/10.1089/dia.2013.0046.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Abrahamian H, Francesconi M, Loiskandl A, Dzien A, Prager R, Weitgasser R. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring. Diabetes Technol Ther. 2004;6:31–7.  https://doi.org/10.1089/152091504322783387.CrossRefPubMedGoogle Scholar
  10. 10.
    Nishimura R, Omiya H, Sugio K, Ubukata M, Sakai S, Samukawa Y. Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet. Diabetes Obes Metab. 2016;18:702–6.  https://doi.org/10.1111/dom.12611.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complicat. 2010;24:79–83.  https://doi.org/10.1016/j.jdiacomp.2009.01.004.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhou J, Zheng F, Guo X, Yang H, Zhang M, Tian H, Guo L, Li Q, Mo Y, Jia W. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs. Diabetes Metab Res Rev. 2015;31:725–33.  https://doi.org/10.1002/dmrr.2661.CrossRefPubMedGoogle Scholar
  13. 13.
    Wan H, Zhao D, Shen J, Lu L, Zhang T, Chen Z. Comparison of the effects of continuous subcutaneous insulin infusion and add-on therapy with sitagliptin in patients with newly diagnosed type 2 diabetes mellitus. J Diabetes Res. 2016;2016:9849328.  https://doi.org/10.1155/2016/9849328.CrossRefPubMedGoogle Scholar
  14. 14.
    FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus glp-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care. 2016;39:973–81.  https://doi.org/10.2337/dc15-2782.CrossRefGoogle Scholar
  15. 15.
    Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, Aso Y. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy. Diabetes Technol Ther. 2014;16:840–5.  https://doi.org/10.1089/dia.2014.0095.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Jia W. Continuous glucose monitoring in China: then, now and in the future. J Diabetes Investig. 2017;8:3–5.  https://doi.org/10.1111/jdi.12521.CrossRefPubMedGoogle Scholar
  17. 17.
    Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol. 2012;11:92.  https://doi.org/10.1186/1475-2840-11-92.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Mianowska B, Fendler W, Tomasik B, Młynarski W, Szadkowska A. Effect of insulin dilution on lowering glycemic variability in pump-treated young children with inadequately controlled type 1 diabetes. Diabetes Technol Ther. 2015;17:605–10.  https://doi.org/10.1089/dia.2014.0392.CrossRefPubMedGoogle Scholar
  19. 19.
    Ebrahim MS, Lawson ML, Geraghty MT. A novel heterozygous mutation in the glucokinase gene conferring exercise-induced symptomatic hyperglycaemia responsive to sulfonylurea. Diabetes Metab. 2014;40:310–3.  https://doi.org/10.1016/j.diabet.2013.12.012.CrossRefPubMedGoogle Scholar
  20. 20.
    Mohan V, Spiegelman D, Sudha V, Gayathri R, Hong B, Praseena K, Anjana RM, Wedick NM, Arumugam K, Malik V, Ramachandran S, Bai MR, Henry JK, Hu FB, Willett W, Krishnaswamy K. Effect of brown rice, white rice, and brown rice with legumes on blood glucose and insulin responses in overweight Asian Indians: a randomized controlled trial. Diabetes Technol Ther. 2014;16:317–25.  https://doi.org/10.1089/dia.2013.0259.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation. Nephrol Dial Transplant. 2014;29:698–705.  https://doi.org/10.1093/ndt/gft377.CrossRefPubMedGoogle Scholar
  22. 22.
    Didangelos T, Margaritidis C, Iliadis F, Hitoglou A, Makedou K, Savopoulos C, Hatzitolios A. Premix insulin analogs preserve good glycemic control in patients with type 2 diabetes previously treated with premix human insulin: a CGM study. In: Diabetes, vol. 64. Alexandria, VA: American Diabetes Association; 2015. p. A245.Google Scholar
  23. 23.
    Ando K, Nishimura R, Tsujino D, Seo C, Utsunomiya K. 24-hour glycemic variations in drug-naïve patients with type 2 diabetes: a continuous glucose monitoring (CGM)-based study. PLoS One. 2013;8:e71102.  https://doi.org/10.1371/journal.pone.0071102.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and Shanghai Scientific and Technical Publishers 2018

Authors and Affiliations

  1. 1.Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Diabetes InstituteShanghai Jiao Tong University, Affiliated Sixth People’s HospitalShanghaiChina

Personalised recommendations